Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG

BRIGHT MINDS BIOSCIENCES

BRIGHT MINDS BIOSCIENCES INC.

BRIGHT MINDS BIOSCIENCES clinical programs — 393 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
Status
Public
HQ
19 Vestry St, New York, NY 10013, US
Employees
12
Programs
1063
Drugs
444
Patents
57
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

BRIGHT MINDS BIOSCIENCES projects

393 ClinicalTrials.gov programs sponsored by BRIGHT MINDS BIOSCIENCES.

BRIGHT MINDS BIOSCIENCES has 393 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

393 programs

Clinical programs

Page 3 of 9

  1. Desipramine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    3 trials

  2. Dextro-Amphetamine Sulfate

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  3. Dextroamphetamine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    4 trials

  4. Disulfiram

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol-Related Disorders

    phase 2 small molecule completed

    1 trial

  5. Disulfiram

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    2 trials

  6. Divalproex Sodium (Depakote)

    BRIGHT MINDS BIOSCIENCES INC.

    Mood Disorders

    phase 2 small molecule completed

    1 trial

  7. Docetaxel

    BRIGHT MINDS BIOSCIENCES INC.

    Prostatic Neoplasms

    phase 2 small molecule completed

    1 trial

  8. Double Trouble in Recovery

    BRIGHT MINDS BIOSCIENCES INC.

    Dual Diagnosis

    phase 2 other completed

    1 trial

  9. Doxazosin

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    2 trials

  10. Doxazosin 4mg/day

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking

    phase 2 small molecule completed

    1 trial

  11. Doxazosin extended release

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine or Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  12. Dronabinol

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Dependence

    phase 2 small molecule terminated

    2 trials

  13. Dronabinol

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use Disorder

    phase 2 small molecule active

    1 trial

  14. Dronabinol 120mg/day

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Smoking

    phase 2 small molecule completed

    1 trial

  15. Dronabinol 30mg/day

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Abuse

    phase 2 small molecule completed

    1 trial

  16. Dynorphin 1 - 13

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 2 small molecule completed

    1 trial

  17. E-cigarettes

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 other completed

    1 trial

  18. EMB-001

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 2 small molecule completed

    2 trials

  19. EVP-6124

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule terminated

    1 trial

  20. Enzalutamide

    BRIGHT MINDS BIOSCIENCES INC.

    Prostate Cancer Metastatic

    phase 2 small molecule completed

    1 trial

  21. Everolimus

    BRIGHT MINDS BIOSCIENCES INC.

    Epilepsy

    phase 2 small molecule active

    1 trial

  22. Evolution: Young Women Taking Charge and Growing Stronger

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 other completed

    1 trial

  23. Extended-Release Naltrexone

    BRIGHT MINDS BIOSCIENCES INC.

    HIV

    phase 2 small molecule completed

    1 trial

  24. FINGER 2.0 multidomain lifestyle-based intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Cognitive Decline

    phase 2 other active

    1 trial

  25. Family Therapy based on Structural Family Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 other completed

    1 trial

  26. Flumazenil

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 small molecule completed

    1 trial

  27. Fluorodopa F 18

    BRIGHT MINDS BIOSCIENCES INC.

    Malignant Brain Neoplasm

    phase 2 small molecule active

    1 trial

  28. Fluoxetine

    BRIGHT MINDS BIOSCIENCES INC.

    Depressive Disorder, Major

    phase 2 small molecule completed

    1 trial

  29. Flupenthixol

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  30. Flupenthixol

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 small molecule completed

    1 trial

  31. G-202

    BRIGHT MINDS BIOSCIENCES INC.

    Glioblastoma Multiforme

    phase 2 small molecule completed

    1 trial

  32. GDCRI/ACM/PG/PhD/10/2013-14

    BRIGHT MINDS BIOSCIENCES INC.

    Chronic Periodontitis

    phase 2 small molecule completed

    1 trial

  33. GSK598809

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule completed

    1 trial

  34. GTS-21

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 small molecule terminated

    1 trial

  35. GW468816

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule completed

    1 trial

  36. Gabapentin

    BRIGHT MINDS BIOSCIENCES INC.

    Benzodiazepine Dependence

    phase 2 small molecule completed

    1 trial

  37. Gabapentin

    BRIGHT MINDS BIOSCIENCES INC.

    Pain

    phase 2 small molecule active

    1 trial

  38. Galantamine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  39. Galantamine

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 small molecule completed

    1 trial

  40. Gamma hydroxybutyric

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 2 small molecule terminated

    1 trial

  41. Gates MRI-TBD06-201

    BRIGHT MINDS BIOSCIENCES INC.

    Pulmonary Tuberculosis

    phase 2 small molecule terminated

    1 trial

  42. Gemcitabine

    BRIGHT MINDS BIOSCIENCES INC.

    Treatment Refusal

    phase 2 small molecule active

    1 trial

  43. Gemcitabine/Cisplatin

    BRIGHT MINDS BIOSCIENCES INC.

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  44. Gepirone

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  45. Guanfacine

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 small molecule completed

    1 trial

  46. Guanfacine

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 2 small molecule completed

    1 trial

  47. Guanfacine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Related Disorders

    phase 2 small molecule completed

    1 trial

  48. Guanfacine

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking

    phase 2 small molecule completed

    2 trials

Frequently asked questions

How many clinical projects does BRIGHT MINDS BIOSCIENCES have?

393 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.